The long QT syndromes: A critical review, new clinical observations and a unifying hypothesis

Progress in Cardiovascular Diseases

Volumn 31, Issue 2, 1988, Pages 115-172

  Jackman, Warren M ^a   Friday, Karen J ^a   Anderson, Jerome L ^a   Aliot, Etienne M ^a   Clark, Mel ^a   Lazzara, Ralph ^a  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ELECTROCARDIOGRAM; HEART ELECTROPHYSIOLOGY; HUMAN; LONG QT SYNDROME; PRIORITY JOURNAL; REVIEW;

ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIA; ELECTROCARDIOGRAPHY; HUMAN; LONG QT SYNDROME; TACHYCARDIA;

EID: 0023705913     PISSN: 00330620     EISSN: None     Source Type: Journal    
DOI: 10.1016/0033-0620(88)90014-X     Document Type: Review

References (429)

1. La tachycardie ventriculaire a deux foyers opposes variables
2. Uber die Deutung des Electrokardiogramms
3. On the time relations of the excitatory process in the ventricle of the heart of the frog
4. A demonstration on man of electromotive changes accompanying the heart beat
5. Significance of the T wave in the electrocardiogram
6. Transmembrane potentials from the human heart
7. Transmembrane potentials of the normal and hypothermic human heart
8. Observations on the origin of the electrocardiogram: Potential variation of single heart muscle fibers in situ
9. Mechanism of ST-segment alteration during acute myocardial injury
10. Effect of high potassium, low potassium and quinidine on QRS duration and ventricular action potential
11. Electrophysiologic des Herzens bei einphasischer Ableitung
12. Der monophasische aktions-strom vom spitze and Basis des Warmbluterherzens und die Theorie der T-Welle des EKG
13. Comparison of cardiac monophasic action potentials recorded by intracellular and suction electrodes
14. Monophasic action potentials in man
15. Right ventricular monophasic action potentials during regular rhythm
16. Intracardiac recording of monophasic action potentials in the human heart
17. Pure monophasic action potentials and their employment in studies of ventricular surface negativity
18. Sequence of repolarization on the ventricular surface in the dog
19. Sequences of early and late phases of repolarization on dog ventricular epicardium
20. Monophasic action potential mapping in human subjects with normal electrograms: Direct evidence for the genesis of the T wave
21. An experimental study on the origin of T waves based on determinations of effective refractory period from epicardial and endocardial aspects of the ventricle
22. Experimental study on the intramural distribution of the excitability cycle and on the form of the epicardial T wave of the dog heart in situ
23. The sequence of normal ventricular recovery
24. Moore EN, Preston JB, Moe GK: Durations of transmembrane potentials and functional refractory periods of canine false tendon and ventricular myocardium. Circ Res 17:259–273
25. Ventricular intramural and epicardial potential distributions during ventricular activation and repolarization in the intact dog
26. The T deflection of the electrocardiogram
27. Functional distribution of right and left stellate innervation to the ventricles
28. Nonuniform recovery of excitability in ventricular muscle
29. Adrenoreceptors in cardiac ventricular muscle and changes in duration of action potential caused by noradrenalin and isoprenalin
30. Electrophysiology and pharmacology of cardiac arrhythmias IX: Cardiac electrophysiologic effects of beta adrenergic stimulation and blockade. Part A
31. Epicardial phenol interrupts refractory period responses to sympathetic but not vagal stimulation in canine left ventricular epicardium and endocardium
32. The QT interval in myocardial infarction and left ventricular hypertrophy
33. QT interval prolongation in acute myocardial infarction
34. Duration of systole in electrocardiogram
35. Effect of pulse rate on the length of systoles and diastoles of the normal human heart in the standing position
36. Studies in the variation of Q-R-S-T interval
37. Normal duration of electrocardiographic ventricular complex
38. The relation of the QT interval to the refractory period, the diastolic interval, the duration of contraction, and the rate of beating in the heart muscle
39. An analysis of the time relations of electrocardiograms
40. Effect of intravenous propranolol on QT interval. A new method of assessment
41. The ventricular paced QT interval—The effects of rate and exercise
42. Influence of heart rate and inhibition of autonomic tone on the QT interval
43. The QT interval—Estimation variability and the effect of physical exercise
44. The QT interval and cycle length: The influence of atropine, hyoscine and exercise
45. An exponential formula for heart rate dependence of QT interval during exercise and cardiac pacing in humans: Reevaluation of Bazett's formula
46. The QT interval during reflex cardiovascular adaptation
47. La ondu U
48. Abnormality of the U wave and of the T-U segment of the electrocardiogram: The syndrome of the papillary muscles
49. Comparison of cardiac monophasic action potentials recorded by intracellular and suction electrodes
50. Purkinje repolarization as a possible cause of the U wave in the electrocardiogram
51. The U wave and aberrant intraventricular conduction: Further evidence for the Purkinje repolarization theory on the genesis of the U wave
52. Electrophysiologic properties of the canine peripheral AV conducting system
53. Regional refractoriness within the ventricular conduction system: An evaluation of the “gate” hypothesis
54. The His-Purkinje electrocardiogram in man: An initial assessment of its uses and limitations
55. The interpretation of the U wave of the electrocardiogram
56. Le role des potentiels tardifs du coeur
57. The initiation of impulses in cardiac muscle
58. Cardiac resting and action potentials recorded with an intracellular electrode
59. Membrane resting and action potentials of single cardiac muscle fibers of the frog ventricle
60. Cellular potentials of intact mammalian hearts
61. Action potentials, afterpotentials and arrhythmias
62. Cellular mechanism for the generation of ventricular arrhythmias by acetylstrophanthidin
63. Correlation between effects of ouabain in the canine electrocardiogram and transmembrane potentials of isolated Purkinje fibers
64. Role of cacium ions in transient inward currents and aftercontractions induced by strophanthidin in cardiac Purkinje fibers
65. Cellular and subcellular mechanisms of cardiac pacemaker oscillations
66. The surprising heart: A review of recent progress in cardiac electrophysiology
67. Inward current channels activated by intracellular Ca in cultured heart cells
68. The steady state TTX sensitive (“window”) sodium current in cardiac Purkinje fibers
69. The effect of tetrodotoxin on potentials of the conducting system in the dog heart
70. The effect of aconitine on the membrane current in cardiac muscle
71. Effects of aconitine on the cardiac membrane potential of the dog
72. Versuche mit Aconitin zum Problem der spontanen Erregurgsbildung im Herzen
73. Bradycarrdia-dependent triggered activity: Relevance to drug-induced multiform ventricular tachycardia
74. Acidosis induced abnormal repolarizations and repetitive activity in isolated dog Purkinje fibers
75. The U wave and afterpotentials in cardiac muscle A panel discussion
76. Genesis of the U wave
77. The U wave of the electrocardiogram
78. Physiologic basis of the U wave
79. Contraction-excitation feedback in myocardium: Physiologic basis and clinical relevance
80. Afterdepolarizations as a mechanism for the long QT syndrome: Electrophysiologic studies of a case
81. Action potential prolongation and induction of abnormal automaticity by low quinidine concentrations in canine Purkinje fibers. Relationship to potassium and cycle length
82. Effects of pacing on triggered activity induced by early afterdepolarizations
83. Can accelerated atrioventricular escape rhythms be explained by delayed afterpotentials?
84. Ambulatory electrocardiography and the diagnosis, evaluation, and treatment of chronic ventricular arrhythmias
85. Coupling intervals of ventricular extrasystoles in relation to the heart rate, the U wave, and the supernormal phase of excitability
86. Ventricular tachyarrhythmias in the long QT syndromes
87. Good, bad or indifferent?
88. QT prolongation and arrhythmia suppression
89. Control of cardiac arrhythmias by selective lengthening of repolarization: Theoretic considerations and clinical observations
90. Delayed ventricular repolarization as an antiarrhythmic principle
91. Quinidine syncope and the delayed repolarization syndrome
92. The U waves in cardiac arrhythmia
93. “Les Torsades de Pointes”: An unusual ventricular arrhythmia
94. Prodromal ventricular premature beats preceded by a diastolic wave
95. The measurement of the QT interval on the electrocardiogram
96. Measurement of the QT interval
97. U wave alternans: An electrocardiographic sign of left ventricular failure
98. Unusual T-wave abnormality: Repolarization alternans associated with hypomagnesemia, acute alcoholism and cardiomyopathy
99. Isolated T-wave alternans
100. A case showing electrical alternans of the T wave without change in the QRS complex
101. Electrical alternation of T wave without change in QRS complex
102. The effect of citrate infusion on the electrocardiogram of the hypothermic and normothermic dog
103. T-wave alternans associated with heart failure and hypomagnesemia in alcoholic cardiomyopathy
104. U wave alternans and increased ventricular irritability
105. Severe citrate intoxication during cardiovascular surgery
106. Right ventricular monophasic action potential during quinidine induced T and U wave abnormalities
107. Incidence and clinical features of the quinidine associated long QT syndrome: Implications for patient care
108. Transient ventricular fibrillation. I. The prefibrillary period during established auricoloventricular dissociation with a note on the phonocardiograms obtained at such times
109. Torsade de Pointes The long-short initiating sequence and other clinical features Observations in 32 patients
110. Torsade de Pointes: A cause of syncope with atrioventricular block
111. Sudden death in cardiomyopathy: Role of bradycardia dependent repolarization changes
112. Les Torsades de Pointe
113. Torsades de Pointes: Serum drug levels and ECG warning signs
114. Clinial, electrocardiographic and follow-up observations in patients having ventricular fibrillation during Holter monitoring. Role of quinidine therapy
115. Quinidine syncope: Paroxysmal ventricular fibrillation occurring during treatment of chronic atrial arrhythmias
116. Etiology, warning signs and therapy of Torsades de Pointes: A study of 10 patients
117. Recurrent ventricular fibrillation precipitated by quinidine
118. Quinidine-induced recurrent ventricular fibrillation: (Quindine syncope) treated with transvenous pacemaker
119. Atypical ventricular tachycardia (Torsades de Pointes) induced by amiodarone: Arrhythmia previously induced by quinidine and disopyramide
120. Torsades de Pointes: Definitions, causative factors, and therapy: Experience with sixteen patients
121. Sudden death recorded during Holter monitoring
122. Torsades de Pointes: Electrophysiologic studies in patients without transient pharmacologic or metabolic abnormalities
123. “Torsade de Pointes” initiated by electrical ventricular stimulation
124. Polymorphous ventricular tachycardia: Clinical characterization, therapy and the QT interval
125. Polymorphous ventricular tachycardia associated with normal and long QT intervals
126. Torsade de Pointes, an atypical ventricular tachycardia
127. Delayed repolarization syndrome
128. Cardiac ballet: Repetition of complex electrocardiographic patterns
129. Tachycardies ventriculaires. Frontieres morphologiques entre les dysrythmies ventriculaires
130. Possible mechanisms of the arrhythmias in the long QT syndrome
131. Preeminence of the left stellate ganglion in the long QT syndrome
132. Torsades de Pointes and mitral valve prolapse
133. The long QT syndrome: Effects of drugs and left stellate block
134. Usefulness of Valsalva maneuver and cold pressor test for the evaluation of arrhythmias in the long QT syndrome
135. Torsades de Pointes versus polymorphic ventriculr tachycardia
136. Polymorphous ventricular tachycardia: Clinical features and treatment
137. The long QT syndrome
138. Quinidine syncope: Torsades de Pointes with low quinidine plasma concentrations
139. Clinical report of the use of quinidine sulfate
140. Quinidine treatment of auricular fibrillation
141. Quinidine therapy of chronic auricular fibrillation: Occurrence and mechanisms of syncope
142. Approaches to sudden death from coronary artery disease
143. Quinidine intoxication occurring during therapy of auricular arrhythmias
144. Treatment of quinidine-induced ventricular fibrillation by closed chest resuscitation and external defibrillation
145. Quinidine-induced syncope
146. Paroxysmal ventricular fibrillation with cardiac recovery in a case of auricular fibrillation and complete heart block while under quinidine sulfate therapy
147. Le syndrome QT long et syncopes par “torsades de pointe”
148. Quinidine syncope: Torsades de pointes due to quinidine: Observations in 31 patients
149. The basis for recurring ventricular fibrillation in the absence of coronary heart disease and its management
150. Quinidine-induced ventricular flutter and fibrillation without digitalis therapy
151. Intoxication with quinidine
152. Quinidine as a cause of sudden death
153. Long-term results of DC reversion of atrial fibrillation
154. Incidence of proarrhythmic effects from quinidine in the outpatient treatment of benign or potentially lethal ventricular arrhythmias
155. Symposium on perspectives on the treatment of ventricular arrhythmias
156. Classification of antiarrhythmic drugs
157. A classification of antiarrhythmic action reassessed after a decade of new drugs
158. Disopyramide-induced Torsades de Pointes
159. Procainamide-induced polymorphous ventricular tachycardia
160. Torsade de Pointes ventricular tachycardia: A complication of disopyramide shared with quinidine
161. Prolinged QT interval, atrioventricular block, and torsade de pointes after antiarrhythmic therapy
162. N-acetylprocainamide causing Torsades de Pointes
163. Disopyramide-induced ventricular fibrillation
164. Torsades de Pointes: Definition and management
165. Delayed repolarization (QT or QTU prolongation) and malignant ventricular arrhythmias
166. Congenital deafness and cardiac arrhythmias
167. Atypical ventricular tachycardia as a manifestation of disopyramide toxicity
168. The action of quinine and quinidine on patients with transient ventricular fibrillation
169. Sudden death in phenothiazine therapy A clinicopathologic study of 12 cases
170. Ventricular fibrillo-flutter (“Torsade de Pointe”): An established electrocardiographic and clinical entity. Report of eight cases
171. The QT interval in drug-free depressed patients
172. Torsades de pointes et reentres provoques par le antiarythumiques
173. Management of recurrent ventricular tachyarrhythmias associated with QT prolongation
174. The long QT syndrome
175. Acta Med Scand
176. Open clinical studies at a referral center: Chronic maintenance tocainide therapy in patients with recurrent sustained ventricular tachycardia refractory to conventional antiarrhythmic agents
177. Congenital prolongation of the QT interval: A family study of three generations
178. The long QT syndrome: A prospective international study
179. Tocainide-induced ventricular fibrillation
180. Torsades de pointes as a manifestation of mexiletine toxicity
181. Safety evaluation of tocainide in the American emergency use program
182. Tocainide for drug-resistant ventricular arrhythmias: Efficacy, side effects, and lidocaine responsiveness for predicting tocainide success
183. Effect of lidocaine on the electrophysiologic properties of ventricular muscle and Purkinje fibers
184. Effects of tocainide and lidocaine on the transmembrane action potentials as related to external potassium and calcium concentrations in guinea pig papillary muscles
185. Electrophysiologic properties of a new antiarrhythmic drug—Tocainide
186. Clinical electrophysiologic effects of tocainide
187. Electrophysiology of oral encainide
188. Malignant ventricular tachyarrhythmias associated with the use of encainide
189. Drug conversion of nonsustained ventricular tachycardia to sustained ventricular tachycardia during serial electrophysiologic studies: Identification of drugs that exacerbate tachycardia and potential mechanisms
190. Comparison of the effects of placebo and encainide on programmed electrical stimulation and ventricular arrhythmia frequency
191. Flecainide induced QT prolongation and ventricular tachycardia
192. Flecainide-induced aggravation of ventricular tachycardia
193. Antiarrhythmic efficacy of encainide in patients with refractory recurrent ventricular tachycardia
194. Ventricular tachycardia associated with flecainide
195. Proarrhythmic effects of the new antiarrhythmic agent flecainide acetate
196. Flecainide Its proarrhythmic effect and expected changes on the electrocardiogram
197. A third class of antiarrhythmic action. Effects on atrial and ventricular intracellular potentials and other pharmacological actions on cardiac muscle of MJ 1999 and AH 3774
198. Electrophysiological and beta receptor blocking effects of MJ 1999 on dog and rabbit cardiac tissue
199. Prolonged QT interval and severe tachyarrhythmias, common features of sotalol intoxication
200. Sotalol-induced delayed ventricular repolarization in man
201. Sotalol prolongation of the QTc interval in hypertensive patients
202. Bloc auriclo-ventriculaire et torsades de pointes apres surdosage par le sotalol
203. Sotalol intoxication with prolonged QT interval and severe tachyarrhythmias
204. Sotalol-induced torsade de pointes
205. Sotalol-induced torsade de pointes
206. Sotalol, hypokalemia, syncope, and Torsades de Pointes
207. Block of inactivated sodium channels and depolarization induced automaticity in guinea pig papillary muscle by amiodarone
208. Amiodarone blocks inactivated cardiac sodium channels
209. Amiodarone-induced ventricular tachycardia
210. Amiodarone-induced polymorphous ventricular tachycardia
211. Amiodarone-induced ventricular fibrillation
212. The QT interval: A predictor of the plasma and myocardial concentrations of amiodarone
213. Amiodarone: Clinical efficacy and electrophysiology during long term therapy for recurrent ventricular tachycardia or ventricular fibrillation
214. Sudden marked QT prolongation after intravenous administration of amiodarone
215. Nine cases of torsades de pointes with bepridil administration
216. Bepridil et torsades de pointes
217. Un case de torsade de pointe sous bepridil
218. Calcium channel blockers that prolong the QT interval
219. QT prolongation and Torsades de Pointes ventricular tachycardia produced by the tetracyclic antidepressant agent maprotiline
220. Thioridazine-induced Torsade de Pointes: Successful therapy with isoproterenol
221. Thioridazine (Mellaril) induced ventricular tachycardia controlled with an artificial pacemaker
222. Electrocardiographic changes and cardiac arrhythmias in patients receiving psychotropic drugs
223. QT prolongation and polymorphous (“Torsades de Pointes”) ventricular arrhythmias associated with organophosphate poisoning
224. Recurrent ventricular tachycardia associated with QT prolongation after mitral valve replacement and its association with intravenous administration of erythromycin
225. QT prolongation and recurrent “torsades de pointes” during erythromycin lactobionate infusion
226. Mexiletine for treatment of Torsades de Pointes
227. Drug induced torsades de pointes: High concordance rate among type IA antiarrhythmic drugs and amiodarone
228. Hypomagnesemic Torsades de Pointes
229. Tachycardie ventriculaire a foyer variable et dyskaliemie
230. Ventricular arrhythmias and hypokalemia
231. Paroxysmal ventricular fibrillation in two patients with hypomagnesemia Treatment by intravenous pacing
232. Transient recurrent ventricular fibrillation due to hypopotassemia with special note on the U wave
233. Electrical alternans of giant U waves with multiple electrolyte deficits
234. Hypomagnesemia and ventricular tachycardia: A complication of ulcerative colitis and parenteral hyperalimentation in a nondigitalized noncardiac patient
235. Multiple risk factor intervention trial Factor changes and mortality results
236. Monophasic action potential studies in human subjects with prolonged ventricular repolarization and long QT syndromes
237. Calcium and the electrocardiogram I. The electrocardiographic manifestations of hypoparathyroidism
238. “Torsade de Pointes” induced by hypocalemia
239. Anorexia nervosa and sudden death
240. Liquid protein diets and Torsades de Pointes
241. Sudden, unexpected death in avid dieters using the liquid protein modified fast diet. Observations in 17 patients and the role of the prolonged QT interval
242. Studies on transient ventricular fibrillation III The prefibrillatory mechanism during established auriculo-ventricular dissociation
243. Transient ventricular fibrillation. III. The effects of bodily rest, atropine sulfate, and exercise on patients with transient ventricular fibrillation during established auriculoventricular dissociation
244. Considerations sur l'electrocardiogramme de la fibrillation ventriculaire
245. The electrocardiogram of the Stokes-Adams attack
246. Adams-Stokes seizures due to ventricular tachydysrhythmias in patients with heart block: Prevalence and problems of management
247. Observations in patients with implanted pacemaker. III. Frequency of ventricular tachycardia as cause of Adams-Stokes attacks and rate of pacing required for its prevention
248. The management of heart block
249. Adams-Stokes syndrome: A review and follow-up study of forty-two cases
250. Congenital deafmutism; functional heart disease with prolongation of the QT interval and sudden death
251. A new familial cardiac syndrome in children
252. Ventricular fibrillation occurring on arousal from sleep by auditory stimuli
253. Syncope and QT prolongation without deafness The Romano-Ward syndrome
254. Grenzstrangganglionitis bei erglichem syndrom der QT verlangerung (Romano-Ward Syndrom)
255. Invasive electrophysiological study in the Jervell and Lange-Nielsen syndrome
256. Heritable QT prolongation without deafness
257. The idiopathic long QT syndrome: Pathogenic mechanisms and therapy
258. Congenital deafmutism, prolonged QT interval, syncopal attacks and sudden death
259. QT prolongation and ventricular arrhythmias with and without deafness in the same family
260. QTU abnormalities sinus bradycardia and Adams Stokes attacks due to ventricular tachyarrhythmia
261. Hereditary prolongation of the QT interval
262. Right ventricular monophasic action potentials in patients with long QT syndrome
263. Electrophysiologic testing in patients with the long QT syndrome
264. Romano-Ward prolonged QT syndrome with intermittent T wave alternans and atrioventricular block
265. Atrioventricular dissociation with prolonged QT interval and syncopal attacks in a 10 year old boy
266. The cardio-auditory syndrome of Jervell and Lange-Nielsen: Report of an additional case with radioelectrocardiographic monitoring during exercise
267. The surdocardiac syndrome Three new cases of congenital deafness with syncopal attacks and QT prolongation in the electrocardiogram
268. Catecholamineinduced severe ventricular arrhythmias with Adams-Stokes syndrome in children: Report of four cases
269. Usefulness of the Valsalva maneuver in management of the long QT syndrome
270. Electrical alternation of the T wave: Clinical and experimental evidence of its relationship with the sympathetic nervous system and with the long QT syndrome
271. Hereditary prolongation of QT intervals in study of two families
272. Hereditary prolongation of the QT interval
273. Familial repolarization myocardiopathy
274. The surdo-cardiac syndrome and therapeutic observations
275. Autonomic maneuvers in hereditary QT interval prolongation (Romano-Ward syndrome)
276. Clinical and pathologic studies in the hereditary syndrome of a long QT interval, syncopal spells, and sudden death
277. Syndrome cardioauditif de Jervell et torsades de pointes
278. The long QT syndrome
279. Idiopathic long QT syndrome: Progress and questions
280. Congenital deafness associated with electrocardiographic abnormalities, fainting attacks, and sudden death: A recessive syndrome
281. Taubstummenheit and taubstummenbildung
282. Genetical aspects of the cardioauditory syndrome of Jervell and Lange-Nielsen (congenital deafness and electrocardiographic abnormalities)
283. Aritmie cardiache rare dell'eta pediatricia
284. Congenital cardiac arrhythmia
285. Congenital cardiac arrhythmia
286. The electrocardiographic abnormality in familial cardiac arrhythmia
287. The heritable syndrome of prolonged QT interval, syncope, and sudden death: Electron microscopic observations
288. A study of the inheritance pattern of Romano-Ward syndrome
289. Unilateral cervicothoracic sympathetic ganglionectomy for the treatment of long QT interval syndrome
290. Efficacy of left cardiac sympathectomy in the treatment of patients with the long QT syndrome
291. Management of tachyarrhythmias with dual-chamber pacemakers
292. Familial QT prolongation syndrome. Convulsive seizures and paroxysmal ventricular fibrillation
293. Idiopathic long QT syndromes in Norway
294. Surdo-cardiac syndrome
295. The surdo-cardiac syndrome
296. Recurrent ventricular fibrillation associated with normal QT intervals
297. Paroxysmal familial ventricular fibrillation
298. Tachyarrhythmic syncopes in children with structurally normal hearts with and without QT-prolongation in the electrocardiogram
299. Effect of exercise on repolarization abnormalities in patients with asymptomatic QT prolongation
300. Sudden unexpected death in three generations
301. Diagnosis and treatment of cardiac arrhythmias in patients with familial long QT syndrome (LQTS) Long term results
302. Ventricular tachycardia and fibrillation associated with normal QT intervals in a teenager without structure [sic] heart disease
303. QT interval in idiopathic prolapsed mitral valve
304. The syndrome associated with the midsystolic click and the late systolic murmur
305. Analysis of QT interval in patients with idiopathic mitral valve prolapse
306. Ventricular arrhythmias in syndrome of balloon deformity of mitral valve: Definition of possible high risk group
307. Mitral valve prolapse: A review of associated arrhythmias
308. Arrhythmias on exercise in patients with abnormalities of the posterior leaflet of the mitral valve
309. Arrhythmias in patients with mitral valve prolapse
310. Adrenergic beta blockade and ECG changes in the systolic click murmur syndrome
311. Autonomic dysfunction in women with mitral valve prolapse syndrome
312. Dysautonomia in mitral prolapse
313. Mitral valve prolapse syndrome and recurrent ventricular tachyarrhythmias
314. Aprindine treatment of recurrent ventricular tachycardia in patients with mitral valve prolapse
315. Electrocardiographic changes in head injuries
316. Concomitant pulsus and U wave alternans associated with head trauma
317. A new electrocardiographic pattern observed in cerebrovascular accidents
318. Electrocardiographic abnormalities in cerebral disorders. Report of six cases and review of the literature
319. Electrocardiographic changes in subarachnoid haemorrhage, meningitis, and intracranial space-occupying lesions
320. Electrocardiographic changes simulating myocardial ischemia and infarction associated with spontaneous intracranial hemorrhage
321. The large upright T wave as an electrocardiographic manifestation of intracranial disease
322. Recurrent torsades de pointes type ventricular tachycardia in intracranial hemorrhage
323. Torsade de Pointe: Atypical ventricular tachycardia complicating subarachnoid hemorrhage
324. Life-threatening arrhythmias in subarachoid hemorrhage
325. Cardiac arrhythmias in acute nervous system disease: Successful management with stellate ganglion block
326. Electrocardiographic changes typical for central nervous system disease after right radical neck dissection
327. Ischemic electrocardiographic changes after truncal vagotomy
328. Cardiac arrhythmias and sudden death in subarachnoid hemorrhage
329. Electrocardiographic wave form and the nervous system
330. Observations on the electrocardiographic changes associated with subarachnoid hemorrhage with special reference to their genesis
331. Sudden unexpected death in infants: Evidence on a lethal cardiac arrhythmia
332. Potential role of QT interval prolongation in sudden infant death syndrome
333. Cardiac sympathetic innervation and the sudden infant death syndrome. A possible pathogenic link
334. Prolonged QT index in “near-miss” sudden death in infancy
335. Sleep apnea and QT interval prolongation—A particularly lethal combination
336. Permanent overdrive pacing for the suppression of recurrent ventricular tachycardia in a newborn with long QT syndrome
337. Unexpected cot deaths
338. QT interval measurements before sudden infant death syndrome
339. The QT interval and sudden infant death syndrome
340. The QT interval throughout the first 6 months of life: A prospective study
341. The quest for the mechanisms of the sudden infant death syndrome: Doubts and progress
342. The role of the QT interval in the sudden infant death syndrome
343. The QT interval in aborted sudden infant death syndrome infants
344. Sudden infant death syndrome: Normal QT interval on ECGs of relatives
345. Sudden infant death syndrome and prolongation of the QT interval
346. The mechanism and nature of ventricular fibrillation
347. Adrenergic effects on ventricular vulnerability
348. Cumulative effects of cycle length on refractory periods of cardiac tissues
349. Temporal dispersion of recovery of excitability in atrium and ventricle as a function of heart rate
350. Mechanism of ventricular arrhythmias caused by increased dispersion of repolarization
351. Role of electrophysiology tsting in managing patients who have ventricular tachycardia unrelated to coronary artery disease
352. Recurrent sustained ventricular tachycardia. 1. Mechanisms
353. Natural and evoked atrial flutter due to circus movement in dogs
354. Circus movement in rabbit atrial muscle as a mechanism of tachycardia II The role of nonuniform recovery of excitability in the occurrence of unidirectional block as studied with multiple microelectrodes
355. Torsades de Pointes: Clinical and experimental observations bearing on mechanism
356. Epinephrine infusion in the congenital long-QT syndrome
357. Recording of monophasic action potentials of the right ventricle in long QT syndromes complicated by severe ventricular arrhythmias
358. Afterpotentials as a cause of the long QT syndrome? Electrophysiologic studies of a case
359. Estimation of ventricular repolarization in man by monophasic action potential recording technique
360. Enregistrement des potentiels d'action monophasiques du ventricule droit dans un cos de QT long et alternance solee de l'onde U
361. Sudden death and the idiopathic long QT syndrome
362. Experimental reproduction of the long QT syndrome
363. Effect of stellectomy and vagotomy on ventricular refractoriness in dogs
364. Neural mechanisms involved in the regulation of ventricular repolarization
365. QT interval syndromes
366. Unilateral stellectomy and sudden death
367. Unilateral stellectomy and dysrhythmias
368. Effects of unilateral stellectomy upon cardiac performance during exercise in dogs
369. De subitaneis mortibus: Observations on the pathophysiology of the long QT syndromes with special reference to the neuropathology of the heart
370. The conduction system in patients with a prolonged QT interval
371. Cardiac ganglionitis associated with sudden unexpected death
372. Adrenergic effects on the QT interval of the electrocardiogram
373. Cardiac Purkinje fibers: Cesium as a tool to block inward rectifying currents
374. Cesium chloride-induced long QT syndrome: Demonstration of afterdepolarizations and triggered activity in vivo
375. Drug-induced torsades de pointes: Clinical and experimental observations bearing in mechanism
376. Rate-dependent changes in extracellular potassium in the rabbit atrium
377. Les variations progressives de l'amplitude de l'electrocardiogramme
378. “Torsade de pointes” tachycardia Re-entry or focal activity?
379. A mechanism of Torsades de Pointes in a canine model
380. The transition to ventricular fibrillation induced by reperfusion after acute ischemia in the dog: A period of organized epicardial activation
381. Torsades de pointes favorisees par stimulations ventriculaires a rhythme lent
382. Overdrive pacing in quinidine syncope and other long QT interval syndromes
383. Temporary control of ventricular arrhythmias by drug-induced sinus tachycardia
384. Torsades de pointe favorisees par l'atropine
385. Magnesium therapy for Torsades de Pointes
386. Quinidine syncope: Report of a case successfully treated with lidiocaine
387. Quinidine syncope. A report of a successful treatment with bretylium tosylate
388. Torsade de Pointes caused by disopyramide and hypokalemia
389. Electrophysiologic antagonism of quinidine and bretylium tosylate
390. Congenital cardiac arrhythmia
391. Primidone in the treatment of the long QT syndrome: QT shortening and ventricular arrhythmia suppression
392. QT interval prolongation, paroxysmal ventricular arrhythmias, and convulsive syncope
393. Stellate ganglion block and stimulation in long QT syndrome, sympathetic dystrophy of the arm and normals
394. Esplin DW: Effects of diphenylhydantoin on synaptic transmission in cat spinal cord and stellate ganglion. J Pharmacol Exp Ther 120:301–323
395. Left stellectomy in the long QT syndrome
396. Termination of malignant ventricular arrhythmias with an implanted ventricular defibrillator in human beings
397. Le syndrome de Romano Ward: Revue de le litterature a propos d'une famillie canadienne-francaise
398. Prevention of Torsades de Pointes with calcium channel blockade in an animal model
399. Syncope par torsade de pointes' au cours d un traitment par la chloroquine. Etudes de l'electrocardiogramme hisien et traitements par le verapamil
400. Dose-ranging trial of N-acetylprocainamide in patients with premature ventricular contractions
401. Torsades de pointes associated with drugs and toxins: Recognition and management
402. Proarrythmic effects of antiarrhythmic drugs
403. The long QT intervals and syndromes
404. Torsades de pointes and other pause-induced ventricular tachycardias: The short-long-short sequence and early afterdepolarizations
405. Polymorphous ventricular tachycardia and early afterdepolarizations: Clinical presentation and therapeutic implications
406. Autonomic modulation of ventricular arrhythmia in cesium-chloride-induced long QT syndrome
407. Differential response of early afterdepolarizations and ventricular tachycardia during right and left stellate stimulation in the dog treated with cesium
408. Magnesium abolishes early afterdepolarizations induced by cesium 4-aminopyridine or quinidine in canine Purkinje fibers
409. Magnesium suppresses early afterdepolarizations and ventricular tachyarrhythmias induced in dogs with cesium
410. Treatment of torsades de pointes with magnesium sulfate
411. Effect of erythromycin on ventricular arrhythmias and ventricular repolarization in idiopathic long QT syndrome
412. QT prolongation and torsades de pointes after the administration of trimethoprim-sulfamethoxazole
413. Torsades de pointes during administration of pentamidine isethionate
414. Torsade de pointes in a patient receiving intravenous vasopressin
415. Polymorphous ventricular tachycardia due to alpha-blockade
416. QT prolongation and torsade de pointes ventricular tachycardia produced by ketanserin
417. Torsade de pointes: An unusual manifestation of chloral hydrate poisoning
418. Torsade de pointes and marked QT prolongation in association with hypothyroidism
419. Torsades de pointes due to Coxsackie B3 myocarditis
420. Amiodarone-induced torsades de pointes
421. Torsades de pointes on sotalol: Incidence and unique clinical features
422. Permanent cardiac pacing in patients with the long QT syndrome